It would seem that the time when machines surpass the ability of humans to do intricate work is almost here. One of Google’s Artificial Intelligence projects is apparently capable of diagnosing the retina of patients to see if they are about to go blind. The search engine company even went so far as to claim that the AI is better than actual doctors at diagnosis.
As Google noted in a blog post about the AI, Diabetic retinopathy is a quickly rising cause of blindness among patients in the world. The disease is treatable, but only if it is caught early enough to respond to treatments. This is where effective diagnosis comes into play.
“Unfortunately, medical specialists capable of detecting the disease are not available in many parts of the world where diabetes is prevalent,” the blog post reads. “We believe that Machine Learning can help doctors identify patients in need, particularly among underserved populations.”
The findings with regards to the diagnostic capabilities of the AI was published in the Journal of the American Medical Association. The paper included proposals on certain potential benefits that machine learning could provide with regards to diagnosing medical problems and even helping to find ways to treat them.
In the case of blindness caused by Diabetic retinopathy, the AI is fed images of retinas, which it will then scan and analyze for any of the telltale sign of impending blindness. After going through 128,000 images of retinas with the traits that led to the condition, the AI was given 10,000 new images to diagnose. Based on the results, the machine was much better at detecting which images posed the biggest threat of blindness for the subjects.
There are significant advantages to having this kind of powerful tool, especially with regards to detecting and curing diseases. However, there is also the startling implication that if a machine can replace vocations as complex and important as those in the medical profession, just how much of human society can AI replace?


Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI
Elliott Investment Management Takes Multibillion-Dollar Stake in Synopsys
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology
AMD CEO Lisa Su Heads to Samsung's South Korea Chip Facility Amid AI Expansion Talks
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
NVIDIA's Feynman AI Chip May Face Redesign Amid TSMC Capacity Crunch
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 



